Phase II Trial of Palbociclib in Recurrent Retinoblastoma-Positive Anaplastic Oligodendroglioma: A Study from the Spanish Group for Research in Neuro-Oncology (GEINO)
Por:
Sepulveda-Sanchez J, Gil-Gil M, Alonso-Garcia M, Salgado M, Vicente E, Barroso C, Sanchez A, Duran G, de las Penas R, Munoz-Langa J, Velasco G, Hernandez-Lain A, Hilario A, Martin M, Benavides M, Oleaga L, Montenegro D, Ruano Y, Sanchez-Gomez P, Martin-Soberon M, Morales-Llombart R, Pachon V, Pineda E
Publicada:
1 oct 2020
Ahead of Print:
1 oct 2020
Resumen:
Background The cell cycle checkpoint G1/S, dependent on cyclin-dependent kinase (CDK) 4 amplification/overexpression and retinoblastoma phosphorylation, is altered in most anaplastic oligodendrogliomas (AOs). Objective We aimed to evaluate the efficacy of palbociclib, an oral inhibitor of CDK4/6 with proven efficacy in breast cancer, in patients with AO. The primary endpoint was progression-free survival at 6 months. Patients and Methods We conducted a multicenter, open-label, phase II trial evaluating the efficacy and safety of palbociclib in patients with AO who progressed on radiotherapy and chemotherapy with histologically and molecularly confirmed grade 3 oligodendroglioma and conserved retinoblastoma protein (pRb) expression by immunohistochemistry. Patients were treated with palbociclib (125 mg/day) for 3/1 weeks on/off. Results Overall, 34 patients were enrolled across 10 hospitals in the Spanish Group of Neuro-Oncology (GEINO) study. The study was stopped early owing to the lack of efficacy, with 74% of evaluable patients progressing within 6 months, which was insufficient to consider palbociclib as an active drug in this population. Within the median follow-up of 12 months, the median progression-free survival was 2.8 months [95% confidence interval (CI) 2.6-3.1] and the median overall survival was 32.1 months (95% CI 5.1-59.2). There were no partial or complete responses; only 13 patients (38%) achieved stable disease as the best response. Palbociclib was well tolerated, with neutropenia (grade 3 or higher: 58.8%) and thrombocytopenia (grade 3 or higher: 14.7%) as the most common adverse events (AEs). Both AEs had no significant impact. Conclusion Despite the good tolerance, palbociclib monotherapy did not show favorable efficacy against recurrent AO.
Filiaciones:
Sepulveda-Sanchez J:
Hosp Univ 12 Octubre, Med Oncol Dept, Avda Andalucia S-N, Madrid 28041, Spain
Gil-Gil M:
Inst Catala Oncol LHospitalet, Med Oncol Dept, Barcelona, Spain
Alonso-Garcia M:
Hosp Univ Virgen del Rocio, Med Oncol Dept, Seville, Spain
Salgado M:
Hosp Univ Ramon y Cajal, Med Oncol Dept, Madrid, Spain
Vicente E:
Hosp Univ Insular Gran Canaria, Med Oncol Dept, Las Palmas Gran Canaria, Spain
Barroso C:
Inst Catala Oncol LHospitalet, Med Oncol Dept, Barcelona, Spain
Sanchez A:
Hosp Univ Leon, Med Oncol Dept, Leon, Spain
Duran G:
Hosp Univ Reg & Virgen de la Victoria, Unidad Gest Clin Interctr Oncol Med, IBIMA, Malaga, Spain
de las Penas R:
Consorcio Hosp Prov Castellon, Med Oncol Dept, Castellon de La Plana, Spain
Munoz-Langa J:
Hosp Univ & Policlin La Fe, Med Oncol Dept, Valencia, Spain
Velasco G:
Univ Complutense Madrid, Chem Sci Fac, Madrid, Spain
Hernandez-Lain A:
Hosp Univ 12 Octubre, Inst Invest Biomed I 12, Dept Pathol Neuropathol, Madrid, Spain
Hilario A:
Universitary Hosp 12 Octubre, Radiol Dept, Madrid, Spain
Martin M:
Hosp Univ Salamanca, Med Oncol Dept, Salamanca, Spain
Benavides M:
Hosp Univ Reg & Virgen de la Victoria, Unidad Gest Clin Interctr Oncol Med, IBIMA, Malaga, Spain
Oleaga L:
Hosp Clin Barcelona, Radiol Dept, Barcelona, Spain
Montenegro D:
Hosp Univ 12 Octubre, Neurooncol Mol Biol Dept, Madrid, Spain
Ruano Y:
Hosp Univ 12 Octubre Res Inst, Mol Pathol Unit, Madrid, Spain
Sanchez-Gomez P:
Inst Salud Carlos III UFIEC, Neurooncol Unit, Madrid, Spain
Martin-Soberon M:
Hosp Univ 12 Octubre, Med Oncol Dept, Avda Andalucia S-N, Madrid 28041, Spain
Morales-Llombart R:
MFAR Clin Res, Barcelona, Spain
Pachon V:
Hosp Univ Ramon y Cajal, Med Oncol Dept, Madrid, Spain
Pineda E:
August Pi i Sunyer Biomed Res Inst IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Barcelona, Spain
Hosp Clin Barcelona, Med Oncol Dept, Barcelona, Spain
|